Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | 3 | — | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Drug common name | Tavapadon |
INN | tavapadon |
Description | Tavapadon (developmental code names CVL-751, PF-06649751) is a dopamine receptor agonist for the treatment of Parkinson's disease., under development by Cerevel Therapeutics who acquired Tavapadon from Pfizer in 2018. It acts as a selective partial agonist of the dopamine D1 (Ki = 8.54 nM) and D5 receptors. It also shows biased agonism for Gs-coupled signaling. As of July 2021, tavapadon is in phase 3 clinical trials for Parkinson's disease.
|
Classification | Small molecule |
Drug class | dopamine D1-like receptors (e.g., D1 and D5 subtypes) agonists/partial agonists and potentiators |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Cc1cc(Oc2ncccc2C(F)(F)F)ccc1-c1c(C)c(=O)[nH]c(=O)n1C |
PDB | — |
CAS-ID | 1643489-24-0 |
RxCUI | — |
ChEMBL ID | CHEMBL3697617 |
ChEBI ID | — |
PubChem CID | 86764100 |
DrugBank | — |
UNII ID | PT4P8MJP8L (ChemIDplus, GSRS) |